Therabron Therapeutics Overview
- Year Founded
-
2007
- Status
-
Out of Business
- Employees
-
9
- Latest Deal Type
-
Out of Business
Therabron Therapeutics General Information
Description
Developer of novel drugs with therapeutic proteins designed to cure respiratory diseases. The company's novel drugs with therapeutic proteins develop a series of recombinant human secretoglobins, enabling patients to access treatments for a range of orphan and more commonplace respiratory diseases impacting people from infancy through adulthood.
Contact Information
Website
www.therabron.comCorporate Office
- 9430 Key West Avenue
- Suite 150
- Rockville, MD 20850
- United States
Corporate Office
- 9430 Key West Avenue
- Suite 150
- Rockville, MD 20850
- United States
Therabron Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Out of Business | 01-Nov-2018 | Completed | Out of Business | |||
| 7. Later Stage VC | 27-Dec-2016 | Completed | Clinical Trials - Phase 2 | |||
| 6. Later Stage VC (Series B) | 18-Nov-2015 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 17-Jun-2014 | Completed | Generating Revenue | |||
| 4. Grant | 24-Sep-2012 | Completed | Startup | |||
| 3. Angel (individual) | 17-Sep-2012 | Completed | Startup | |||
| 2. Angel (individual) | 10-Nov-2011 | $315K | $315K | Completed | Startup | |
| 1. Grant | 29-Oct-2010 | $244K | Completed | Startup |
Therabron Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A4 | ||||||||
| Series A3 | ||||||||
| Series A2 | 89,683 | $0.001000 | $6.3 | $6.3 | 1x | $6.3 | 2.2% | |
| Series A1 | 116,279 | $0.001000 | $2.15 | $2.15 | 1x | $2.15 | 2.85% |
Therabron Therapeutics Patents
Therabron Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2016205430-A1 | Recombinant human cc10 protein facilitates repair and protects against damage to the respiratory epithelium due to exposure to both cigarette and other smoke | Inactive | 15-Jun-2015 | ||
| WO-2016133560-A1 | Recombinant human cc10 protein for treatment of influenza and ebola | Inactive | 16-Feb-2015 | ||
| US-20160159870-A1 | Compositions and methods of use for recombinant human secretoglobins | Active | 15-Mar-2013 | ||
| US-9765127-B2 | Compositions and methods of use for recombinant human secretoglobins | Active | 15-Mar-2013 | ||
| AU-2014233116-A1 | Improved methods of use for recombinant human secretoglobins | Inactive | 15-Mar-2013 | C07K14/47 |
Therabron Therapeutics Signals
Therabron Therapeutics FAQs
-
When was Therabron Therapeutics founded?
Therabron Therapeutics was founded in 2007.
-
Where is Therabron Therapeutics headquartered?
Therabron Therapeutics is headquartered in Rockville, MD.
-
What is the size of Therabron Therapeutics?
Therabron Therapeutics has 9 total employees.
-
What industry is Therabron Therapeutics in?
Therabron Therapeutics’s primary industry is Drug Discovery.
-
Is Therabron Therapeutics a private or public company?
Therabron Therapeutics is a Private company.
-
What is Therabron Therapeutics’s current revenue?
The current revenue for Therabron Therapeutics is .
-
How much funding has Therabron Therapeutics raised over time?
Therabron Therapeutics has raised $16.8M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process